2021 World Stem Cell Summit

Members of our Cell, Tissue, and Gene Therapies team presented on two focused discussions at the World Stem Cell Summit. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders.

Mike Druckman led the panel session "The Amazing Reverse Migration of Products from 361 to 351," with Jane Kalinina and visiting expert Rebeccah Brown, MiMedx, to discuss the regulatory shift in marketing HCT/Ps and the opportunities and pitfalls for seeking Section 351. In addition, Mike Druckman and global panelists from Russia, Australia, and Germany presented on global legal implications of cell, tissue, and gene therapies during the panel session, "A World Compass for Commercializing, Manufacturing and Marketing Cell and Gene Therapies."

For more information, click here.

Back To Listing